BIOSECURE Act: Protecting U.S. Security vs. Losing Our Edge

The BIOSECURE Act, aimed at restricting federal contracts and funding to foreign biotechnology companies from nations deemed adversarial to U.S. interests, such as China, is reshaping the landscape of U.S. biotech. As a preclinical CRO in San Diego that collaborates with clients ranging from local startups to large pharmaceutical companies, we see both the threats and opportunities this legislation presents. The Act aims to safeguard national security, but it risks restricting global partnerships and jeopardizing scientific advancements and innovation.

While the Act primarily targets foreign entities, its effects ripple through the domestic biotech sector. U.S. companies that engage in partnerships or rely on services from foreign biotechnology providers will face new restrictions on federal contracts and funding. This creates a need for companies to reassess their collaborations and adapt their operations to ensure compliance while minimizing disruptions to their research and development efforts.

To better understand these challenges, here are some specific examples of how the BIOSECURE Act could impact key partnerships and services:

Contract Research Organizations (CROs):

• Partnerships with Chinese firms like WuXi AppTec, which provide preclinical research and clinical trial support.
• Example: A U.S. biotech company using WuXi’s services for preclinical toxicology studies might face penalties if federal funding is used to support these collaborations.

Contract Development and Manufacturing Organizations (CDMOs):

• Services from companies such as WuXi Biologics, which manufacture active pharmaceutical ingredients and biologics.
• Example: A U.S. pharmaceutical company relying on WuXi Biologics for the production of monoclonal antibodies could be forced to reallocate production to domestic or allied facilities.

Good Manufacturing Practices (GMP) Facilities:

• Chinese GMP-certified facilities are often engaged for cost-effective manufacturing of APIs and cell or gene therapy products.
• Example: A partnership with BGI Genomics for sequencing-based companion diagnostics could be disrupted if deemed non-compliant with federal funding restrictions.

Technology Licensing and Data Sharing Agreements:

• Licensing technologies from firms like Complete Genomics (a subsidiary of BGI Group) for genomics sequencing and analysis.
• Example: A university research lab using equipment from BGI Group for federally funded genomics studies might need to replace this equipment to maintain funding eligibility. This issue would particularly impact labs in the U.S. that use equipment manufactured or distributed by Complete Genomics.

At Glint Lab, as part of our due diligence in ongoing partnership discussions, we addressed this concern directly with Complete Genomics. They have confirmed that they are actively working on solutions to eliminate any potential future impact on their clients.

Misagh Naderi, PhD – Glint Lab CEO

Main goals of Introducing BIOSECURE Act

• Protecting Sensitive Data: The Act aims to prevent the transfer of American genomic and biotechnological data to foreign adversaries, thereby safeguarding against potential misuse or exploitation.
• Reducing Dependency on Foreign Entities: By limiting federal contracts and funding to specified foreign biotech firms, the legislation seeks to decrease U.S. reliance on external sources for critical biotechnology services and products.
• Strengthening Domestic Biotechnology Infrastructure: The Act encourages investment in U.S.-based research, development, and manufacturing capabilities, aiming to bolster the nation’s self-sufficiency in the biotech sector.

Unintended Consequences Across Various Sectors

Biotech and Pharmaceutical Industries

• Supply Chain Disruptions: Many U.S. companies rely on foreign Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) for cost-effective research and production. The Act’s restrictions could necessitate a realignment of these supply chains, potentially causing delays which can be very costly for companies and patients alike.
• Higher Production Costs: Transitioning to domestic or alternative international partners may result in increased production expenses, as these alternatives might not offer the same cost efficiencies as the previously utilized foreign entities.
• Increased Compliance Costs: Companies will need to conduct thorough audits of their partnerships and contracts to ensure compliance with the new regulations, leading to additional operational expenses.

Scientific Community

• Impact on Collaboration: The Act may hinder international research collaborations, as partnerships with certain foreign entities become restricted. This could slow scientific progress and innovation.
• Data Sharing Challenges: Limitations on collaborations may impede the sharing of critical scientific data, affecting research outcomes and the development of new therapies.

Patients and Healthcare

• Drug Availability: Disruptions in the supply chain and increased production costs could lead to shortages or delays in the availability of certain medications and treatments.
• Healthcare Costs: The financial burden of restructuring supply chains and ensuring compliance may be passed on to consumers, potentially increasing healthcare costs and limiting access to essential treatments.

Support for the BIOSECURE Act

Policy Advocates’ Perspective

• Enhancing National Security: Proponents argue that the Act is crucial for protecting sensitive genetic data and intellectual property from foreign adversaries. By restricting federal engagements with certain foreign biotechnology firms, the legislation aims to minimize risks associated with data breaches and espionage.
• Building Domestic Capacity: The Act is seen as a catalyst for fostering domestic research and development (R&D) and manufacturing capabilities. By reducing reliance on foreign entities, it encourages investment in U.S.-based facilities and talent, potentially leading to job creation and technological advancements within the country.
• Gradual Implementation Timeline: The inclusion of an eight-year transition period allows companies ample time to adjust their supply chains and partnerships. This phased approach is intended to mitigate immediate disruptions, providing a balanced pathway toward achieving the Act’s objectives without causing undue harm to existing operations.

Industry Support

• Endorsement from Biotechnology Innovation Organization (BIO): BIO, a leading industry group, has expressed support for the Act, particularly appreciating the extended compliance timeline. This endorsement reflects a recognition of the need to address national security concerns while maintaining industry stability.
• Potential for Long-Term Economic and Technological Leadership: Supporters believe that by investing in domestic biotechnology infrastructure and reducing dependency on foreign services, the U.S. can enhance its global competitiveness. This strategic shift is anticipated to position the nation as a leader in biotech innovation and production, with positive implications for economic growth and technological advancement.

BIO applauds this work and supports this BIOSECURE legislation.

John F. Crowley – BIO President and CEO

Criticism and Concerns for the BIOSECURE Act

Overly Broad Scope

• Overly Broad Scope: Critics argue that the Act’s broad restrictions could inadvertently encompass companies that do not pose a national security threat. By targeting firms based solely on their country of origin, the legislation may overlook the complexities of global biotechnology collaborations and the nuanced nature of international partnerships.

Impact on Innovation and Competition

• Impact on Innovation and Competition: There is concern that the Act could stifle innovation by limiting access to international expertise and technologies. Critics argue that restricting collaborations with foreign biotech firms may limit competitive pressures that drive innovation, ultimately making the domestic sector less dynamic.

Economic Implications

• Economic Implications: The Act may have economic repercussions, particularly for U.S. companies that have established relationships with the targeted foreign entities. Disrupting these partnerships could lead to financial losses and hinder the growth of U.S. biotech firms that rely on international collaborations for research and development.

Diplomatic Relations

• Diplomatic Relations: Some critics warn that the Act could strain diplomatic relations with countries whose companies are affected. By imposing unilateral restrictions, the U.S. risks retaliatory measures that could impact broader economic and scientific collaborations, potentially isolating the U.S. in the global biotech community. For example, affected countries may impose reciprocal trade restrictions or limit U.S. access to critical raw materials and technologies, further complicating international cooperation.

The U.S. risks falling behind and being left out of major international collaborations

W. John Kress, PhD – the Smithsonian Institution curator emeritus

Impact on U.S. Companies

The BIOSECURE Act introduces significant challenges for U.S. biotech and biopharma companies engaged with Chinese contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and Good Manufacturing Practices (GMP) facilities. By restricting federal funding and contracts with entities linked to countries designated as foreign adversaries, such as China, the Act necessitates a strategic reassessment of global collaborations.

Impacts on CROs and CDMOs

U.S. companies frequently collaborate with Chinese CROs and CDMOs for cost-effective drug discovery, preclinical research, and clinical trial support. Notable organizations like WuXi AppTec and BGI Group, often integral to these partnerships, face potential restrictions under the Act. This scenario compels companies to identify and transition to alternative service providers, such as a clinical or preclinical CRO in San Diego, Boston, Seattle, the Bay Area, Chicago, Austin, and other major U.S. biotech hubs. Without timely action, this transition could disrupt project timelines, escalate costs, and require comprehensive due diligence to ensure compliance.

Challenges in GMP Manufacturing

Chinese GMP-certified facilities are pivotal in producing active pharmaceutical ingredients (APIs), biologics, and cell and gene therapy products. The Act’s constraints may limit access to these facilities, prompting U.S. companies to restructure their supply chains. Such adjustments could lead to manufacturing delays, increased production expenses, and strained relationships with existing partners.

This is based on a flawed premise! Even if we wanted the data we are physically unable to obtain it… If you really wanted to protect data, I don’t think this bill does a good job of that.

Rob Tarbox – Complete Genomics VP of product and marketing

Role of a Domestic Clinical and Preclinical CRO in Supporting the BIOSECURE Act

Every clinical or preclinical CRO in key biotech hubs like San Diego, Boston, Seattle, the Bay Area, Chicago, and Dallas, as well as emerging innovation centers, can play a critical role in supporting U.S. biotech and pharma companies in navigating this changing landscape. These organizations provide specialized services, ranging from preclinical drug development and toxicology studies to advanced histopathology and bioanalytical solutions, which help U.S.-based biotech companies reduce reliance on international partnerships.

The increased reliance on domestic CROs presents an opportunity for these organizations to expand capacity and innovate, ensuring the U.S. biotech industry remains competitive on the global stage. For example, at Glint Lab, a preclinical CRO in San Diego, we have successfully scaled up our services to accommodate companies that are proactive about these regulatory changes, ensuring a smooth transition without major delays.

Additionally, this is an opportunity for U.S. manufacturers in reagents, lab-automation tools, diagnostics, and university technology transfer offices to collaborate, contributing to the exponential growth of U.S. capabilities in becoming self-sustaining. By working closely with U.S. biotech companies, domestic CROs can tailor their services to meet specific research and development needs, further enhancing the ability of the U.S. biotech industry to maintain momentum amidst these changes.

Glint Lab’s Strategy as an Innovative Preclinical CRO in San Diego

As U.S. companies adapt to these new regulations, Glint Lab stands ready to support them through this pivotal time. We are proactively addressing the challenges posed by the BIOSECURE Act with our vendors and partners. We have the expertise to accommodate clients who are restructuring their CRO relationships and require seamless protocol transfers.

While U.S. companies have eight years to restructure their workflows, swift action is essential to navigate the broader global changes already in motion. The recent 16th BRICS Summit and the ongoing U.S.-China trade war underscore the urgency of adapting quickly to maintain competitiveness and mitigate risks.

To meet the growing U.S.-based preclinical CRO demand, we have expanded our capabilities in San Diego and are collaborating with cutting-edge research labs and startups across the U.S. in developing new capabilities in robotics, AI-based lab automation, tissue engineering, organoid models, and spatial biology. We are also actively planning to extend our presence to other U.S. geographies in the near future. Glint Lab remains committed to delivering cutting-edge histopathology and digital pathology services, enabling clients to navigate regulatory changes while maintaining excellence in their research endeavors.

Looking Ahead

As the BIOSECURE Act reshapes the landscape of biotechnology, a crucial question emerges: Which countries stand to gain the most from these sweeping changes, and how will the shifting dynamics in world politics, such as the recent 16th BRICS Summit, influence global collaboration in biotech? These are questions that we hope to address in a different article soon, stay tuned!